Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Somatropin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 05, 2020
Lead Product(s) : Somatropin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Growth Hormone Replacement Therapy for Retried Professional Football Players
Details : Undisclosed
Product Name : Norditropin
Product Type : Hormone
Upfront Cash : Inapplicable
October 10, 2019
Lead Product(s) : Somatropin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 11, 2019
Lead Product(s) : Somatropin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 06, 2019
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 14, 2017
Lead Product(s) : Somatropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : CinnaTropin
Product Type : Hormone
Upfront Cash : Inapplicable
July 19, 2017
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 19, 2017
Lead Product(s) : Somatropin
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Peking Union Medical College Hospital | Peking University First Hospital | Hebei General Hospital | The Second Hospital of Hebei Medical University | Qilu Hospital of Shandong University | Second Affiliated Hospital, Zhejiang University | The First Affili
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 07, 2017
Lead Product(s) : Somatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Peking Union Medical College Hospital | Peking University First Hospital | Hebei General Hospital | The Second Hospital of Hebei Medical University | Qilu Hospital of Shandong University | Second Affiliated Hospital, Zhejiang University | The First Affili
Deal Size : Inapplicable
Deal Type : Inapplicable